A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First Line Advanced RCC
May 16, 2012
- Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment -
- First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC -
- Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability -